SADDLE BROOK, N.J., Oct. 19, 2010 (GLOBE NEWSWIRE) -- Herborium Group, Inc., (Pink Sheets:HBRM) , a Botanical Therapeutics™ company, today announced it has filed all Pink OTC® Market requirements to qualify as a company with Current Information available on pinksheets.com – the highest tier attainable for a Pink Sheets listed company.
"I am pleased our regulatory compliance initiative has successfully filed all required OTC Market documents to raise our tier status to Current Information," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "We expect to continue our regulatory compliance initiative to achieve a Bulletin Board reporting status as soon as it is practical. I will update shareholders on this initiative as we progress."
Herborium develops and licenses proprietary, all natural botanically based medicines. The Company's differential advantage is its ability to distinguish its Botanical Therapeutics® through clinical-trial validation, which confirms their safety and efficacy. The Company plans to capitalize on recent U.S. Food & Drug Administration (FDA) guidelines (FDA Guidance for Industry: Botanical Drug Products), which enable the advertising of its products' medical claims.
AcnEase®, the Company's flagship product, is a proprietary, systemically acting Botanical Therapeutic targeting acne and rosacea in both females and males of all ages. AcnEase has proven safe and effective through rigorous clinical testing. ().
"With the opinion letter regarding completeness of disclosure posted, Pink OTC Markets will now verify that quarterly and annual reports have been posted per its policies. We expect this verification of our filings to help build investor confidence in our public reporting. We also look forward to soon sharing with investors the Company's new marketing strategy to gain a significant share of the world's natural medicines market," Olszewski concluded.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit and .
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
CONTACT: Herborium Group, Inc. Dr. Agnes P. Olszewski, President & CEO (201) 647-3757